Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator.
Zenz
W
W
Muntean
W
W
Zobel
G
G
Grubbauer
H M
HM
Gallistl
S
S
D000818:Animals; D016470:Bacteremia / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D017395:Plasminogen Activator Inhibitor 1 / Q000502:physiology*; D011486:Protein C / Q000627:therapeutic use; D020151:Protein C Deficiency; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D012772:Shock, Septic / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; D011994:Recombinant Proteins; D013300:Streptokinase; D010959:Tissue Plasminogen Activator